Result
recent diab: increased remission vs. placebo diabetic: improved C-peptide vs. placebo 5-10 mg/kg/day (Feutren et al., 1986; De Filippo et al., 1996; Assan et al., 1985; Chase et al., 1990; CanadianEuropean Randomized Control Trial Group, 1988) protection (Laupacis et al., 1983; Like et al., 1983) Nicotinamide pre-diab: protection recent diab: remission diabetic: no remission 500 mg/kg 3-4x/wk (Yamada et al., 1982; Kim et al., 1997) pre-diab: no difference in incidence vs. placebo diabetic: increase in basal C-peptide vs placebo 1-100 mg/kg daily (Pozzilli et al., 1996; Lampeter et al., 1998; Gale et al., 2004) no protection (Hermitte et al., 1989; Pan et al., 1995) BCG pre-diab: protection 0.25-1 mg 1x (Kim et al., 1999; Harada et al., 1990; Shehadeh et al., 1994) oral insulin pre-diab: protection 1 mg, 1x-2x/wk (Zhang et al., 1991; Hartmann et al., 1997; Homann et al., 1999; Ramiya et al., 1997; Bergerot et al., 1996) pre-diab: similar rate in onset, ongoing recent diab: no difference in HbA1c, C-peptide, insulin requirements vs. placebo 7.5 mg/day 2.5-7.5 mg/day (Skyler et al., 2005; Pozzilli et al., 2000; Chaillous et al., 2000) no protection (Mordes et al., 1996) nasal insulin pre-diab: protection dose not reported, 1-7x/wk (Harrison et al., 1996) pre-diab: no acceleration of disease diabetic: ongoing 1.6 mg/day 2-7x/wk 3-18 mg/day (Harrison et al., 2004; Skyler et al., 2001) pentoxifylline pre-diab: protection 160 mg/kg/day (Liang et al., 1998 Bjork et al., 1996; Greenwood et al., 1976) protection (Vlahos et al., 1991) intravenous Ig pre-diab: protection 1 mg 3x/wk for 4 wks (Bruley-Rosset et al., 2003) recent diab: reduced insulin requirements and higher serum C-peptide levels vs. placebo 0.4 g/kg/day for 1 wk, then 1x/wk for up to 6 mo (Panto et al., 1990) Supplemental References
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